| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1074248411424145 |
| P698 | PubMed publication ID | 22064668 |
| P50 | author | John P Murad | Q56997598 |
| P2093 | author name string | Fadi T Khasawneh | |
| Harold J Ting | |||
| Enma V P Espinosa | |||
| P2860 | cites work | Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina | Q58230345 |
| BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN | Q58481581 | ||
| Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal | Q59065336 | ||
| Cloning and expression of cDNA for a human thromboxane A2 receptor | Q24311759 | ||
| G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C | Q24324791 | ||
| COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression | Q24536398 | ||
| Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation | Q24562692 | ||
| Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation | Q24596717 | ||
| Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist | Q28167658 | ||
| Role of prostacyclin in the cardiovascular response to thromboxane A2 | Q28192832 | ||
| Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin | Q28195607 | ||
| Mapping of a ligand-binding site for the human thromboxane A2 receptor protein | Q28205029 | ||
| G13-mediated signaling as a potential target for antiplatelet drugs | Q28211909 | ||
| Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-HT6) and the alpha subunit of GS protein | Q28237275 | ||
| Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway | Q28276490 | ||
| Mechanism of action of fibrates on lipid and lipoprotein metabolism | Q28288187 | ||
| GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro | Q28341988 | ||
| Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling | Q28571919 | ||
| Inositol trisphosphate, a novel second messenger in cellular signal transduction | Q29618048 | ||
| The role of protein kinase C in cell surface signal transduction and tumour promotion | Q29618532 | ||
| Thromboxane and the thromboxane receptor in cardiovascular disease | Q33899567 | ||
| An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro | Q34185192 | ||
| GAPs for rho-related GTPases | Q34319579 | ||
| Aspirin as an antiplatelet drug | Q34338650 | ||
| Signaling and regulation of the platelet glycoprotein Ib-IX-V complex | Q34616663 | ||
| Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide | Q34986893 | ||
| Acetylation of prostaglandin synthase by aspirin | Q35085661 | ||
| Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling | Q35579014 | ||
| Roles of G-protein-coupled receptor dimerization | Q35622424 | ||
| Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis | Q36294176 | ||
| Antagonism of thromboxane receptors by diclofenac and lumiracoxib | Q36358638 | ||
| From the design to the clinical application of thromboxane modulators | Q36419627 | ||
| Protease activated receptors: clinical relevance to hemostasis and inflammation | Q36720123 | ||
| Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane A2 receptor in insect cells | Q36823316 | ||
| Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets | Q37010020 | ||
| Aspirin resistance: focus on clinical endpoints | Q37334879 | ||
| 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor | Q37341093 | ||
| Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. | Q37370008 | ||
| Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. | Q37392176 | ||
| The thromboxane/endoperoxide receptor (TP): the common villain | Q37737688 | ||
| Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors | Q37738868 | ||
| Platelets at work in primary hemostasis. | Q37865759 | ||
| Thromboxane, prostaglandin and leukotriene receptors | Q38272494 | ||
| Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. | Q38325669 | ||
| Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor | Q39019862 | ||
| The opsin family of proteins | Q39480645 | ||
| Clinical implications of prostaglandin and thromboxane A2 formation (2). | Q39519430 | ||
| Low expression of cell-surface thromboxane A2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes | Q40133308 | ||
| Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein | Q40256331 | ||
| The G12 family of G proteins as a reporter of thromboxane A2 receptor activity | Q40328440 | ||
| Oligomerization of the alpha and beta isoforms of the thromboxane A2 receptor: relevance to receptor signaling and endocytosis | Q40422541 | ||
| Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation | Q40506646 | ||
| Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function | Q40651409 | ||
| Antiarrhythmic drugs and torsade de pointes | Q40807714 | ||
| Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. | Q40978901 | ||
| Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms | Q40990740 | ||
| Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism | Q41015991 | ||
| Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling | Q41216013 | ||
| Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds | Q41572758 | ||
| 14-3-3zeta interacts with human thromboxane receptors and is involved in the agonist-induced activation of the extracellular-signal-regulated kinase | Q42170095 | ||
| Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3′-pyridinylmethyl)benzofuran-2-carboxylate | Q42246687 | ||
| Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin | Q42472257 | ||
| Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe | Q42554632 | ||
| Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins. | Q42602291 | ||
| Glybenclamide: an antidiabetic with in vivo antithrombotic activity | Q42880731 | ||
| Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles | Q43730032 | ||
| Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling | Q43860082 | ||
| Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release | Q44167942 | ||
| Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function | Q44284991 | ||
| Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach | Q44292843 | ||
| TRA-418, a novel compound having both thromboxane A(2) receptor antagonistic and prostaglandin I(2) receptor agonistic activities: its antiplatelet effects in human and animal platelets | Q44545094 | ||
| Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets | Q44730150 | ||
| Structural and functional characterization of the first intracellular loop of human thromboxane A2 receptor | Q44786762 | ||
| Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling. | Q44960382 | ||
| Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet | Q45064186 | ||
| Effects of KP-496, a novel dual antagonist for cysteinyl leukotriene receptor 1 and thromboxane A2 receptor, on Sephadex-induced airway inflammation in rats. | Q45989071 | ||
| Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug | Q46061444 | ||
| A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids | Q46307406 | ||
| Effect of inhibitors of arachidonic acid conversion in platelets on thrombin-fibrinogen interaction and thrombin tolerance | Q46472175 | ||
| The Lsc RhoGEF mediates signaling from thromboxane A2 to actin polymerization and apoptosis in thymocytes | Q46482145 | ||
| The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. | Q46566202 | ||
| Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein | Q46741746 | ||
| Gbeta 5gamma 2 is a highly selective activator of phospholipid-dependent enzymes. | Q52972449 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 248-259 | |
| P577 | publication date | 2011-11-07 | |
| P1433 | published in | Journal of Cardiovascular Pharmacology and Therapeutics | Q1855644 |
| P1476 | title | Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting | |
| P478 | volume | 17 |
| Q35772240 | Brain changes associated with thromboxane receptor antagonist SQ 29,548 treatment in a mouse model |
| Q34389439 | Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. |
| Q30360845 | Invited review: GPCR structural characterization: Using fragments as building blocks to determine a complete structure. |
| Q42017198 | Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists |
| Q27023818 | Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature |
| Q38899898 | Regulation of inflammation by lipid mediators in oral diseases |
| Q90227640 | Structural basis for ligand recognition of the human thromboxane A2 receptor |
| Q58794697 | TBXA2R gene variants associated with bleeding |
| Q46974995 | The association of thromboxane A2 receptor with lipid rafts is a determinant for platelet functional responses |
| Q41002708 | Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration |
Search more.